Advanced Urothelial Carcinoma research hub

A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

This study is looking at new treatments for advanced bladder cancer that has spread. It combines pembrolizumab and enfortumab vedotin, sometimes with other new medicines, to see if they are safe and work well as a first treatment.